SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InterMune (nasdaq)ITMN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: IRWIN JAMES FRANKEL who wrote (117)7/26/2001 11:01:04 PM
From: Biomaven  Read Replies (2) of 508
 
Thanks for the background, IJ. This isn't an area I know the history of, so your comments are helpful.

Is it clear that ITMN would have the rights to a pegylated version of Infergen?

Another competitor here might also eventually be HGSI with Albuferon, their albumin fusion with alpha interferon. They seem very enthusiastic about it indeed. Here's an early release describing it:

hgsi.com

It potentially has a much longer half-life than even the pegylated interferons.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News